A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder.

Trial Profile

A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Pralatrexate (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 04 Jul 2012 Planned number of patients changed from 41 to 50 as reported by EudraCT.
    • 12 Dec 2011 Actual end date (September 2011) added as reported by ClinicalTrials.gov.
    • 12 Dec 2011 Actual patient number is 30 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top